Book summary “ASPEN Parenteral Nutrition Handbook, Third Edition”: summary

Introduction

You face complex clinical challenges when caring for patients who cannot absorb adequate nutrients through the gastrointestinal tract due to failure, obstruction, or resection. Without proper intervention, these patients rapidly develop severe malnutrition and metabolic failure that increase morbidity and mortality risks.

The definitive clinical standard guide by the American Society for Parenteral and Enteral Nutrition for safe prescription, compounding, vascular access management, and administration of parenteral nutrition therapy across care settings.

Phil Ayers and the American Society for Parenteral and Enteral Nutrition establish rigorous professional standards and safety consensus recommendations to govern this high-risk therapy. You will learn how to navigate nutrition assessment, select vascular access devices, calculate precise formulations, and manage compounding and administration safely.

• How do you diagnose malnutrition using standardized criteria and inflammation parameters?
• What clinical indications justify initiating parenteral nutrition therapy?
• How do you prevent catheter-related bloodstream infections during vascular access management?
• What strategies ensure safe compounding and prevent nutrient incompatibilities?

1. Nutrition Assessment and Malnutrition Diagnosis

Standardized screening and diagnostic criteria identify malnutrition through phenotypic indicators, etiologic factors, and inflammation parameters. Assessment incorporates anthropometric measurements, biochemical data such as albumin and prealbumin, and physical examinations like the nutrition-focused physical examination to grade severity in adult and pediatric populations.

Adult Malnutrition Characteristics

Adult malnutrition is diagnosed when a patient demonstrates at least two of six specific clinical characteristics. The six characteristics include weight loss, insufficient energy intake, loss of body fat, loss of muscle mass, local or generalized fluid accumulation, and reduced hand grip strength. These characteristics are assessed using a combination of medical history, physical exams, and anthropometric data.

Specific thresholds guide your diagnostic evaluation:

• 10% weight loss within 6 months or 5% within 1 month
• 10 lb weight loss within 6 months
• BMI less than 18.5 kg/m2

You must follow structured steps to confirm the diagnosis:

• Review patient medical record and conduct verbal discussions with the patient or caregiver.
• Perform a nutrition-focused physical examination to check muscle, fat, and fluid status.
• Evaluate presence of at least two of the six designated malnutrition characteristics to confirm diagnosis.

Inflammation alters metabolic processes and invalidates traditional visceral proteins as markers of nutrition status. Inflammatory states trigger cytokine-mediated alterations such as elevated energy expenditure and lean tissue catabolism. Negative acute-phase proteins like albumin and prealbumin decrease due to inflammation rather than solely indicating poor nutrition, meaning they should not be used in isolation to assess nutritional status.

The Global Leadership Initiative on Malnutrition utilizes a combination of phenotypic and etiologic criteria to diagnose undernutrition. To establish a malnutrition diagnosis under this framework, a patient must present with at least one phenotypic criterion and at least one etiologic criterion. Phenotypic criteria include weight loss, low body mass index, and reduced muscle mass, while etiologic criteria encompass reduced food intake or assimilation and inflammation.

You apply this global framework directly at the bedside:

• Assess patient for at least one phenotypic criterion such as weight loss, low BMI, or reduced muscle mass.
• Assess patient for at least one etiologic criterion such as reduced food intake or inflammation.
• Categorize severity as stage 1 moderate or stage 2 severe based exclusively on phenotypic criteria.

Pediatric Assessment and Timing of Intervention

Pediatric malnutrition is defined as an imbalance between nutrient requirements and intake that creates cumulative deficits affecting growth and development. Assessment in children aged one month to eighteen years heavily relies on accurate anthropometric measurements plotted against standard growth charts using z-scores. Nutrition-focused physical examinations and dynamic changes in weight or length velocity over time are critical for detecting growth faltering, including head circumference for infants under 2 years of age.

You must execute precise pediatric measurement protocols:

• Record weight, height, BMI, and mid-upper arm circumference on admission and serially.
• Plot individual anthropometric variables against population reference curves to obtain the z-score.
• Monitor for a decline in z-score greater than one as an indication of faltering growth.

The optimal timing for initiating parenteral or enteral nutrition depends on the patient's underlying nutrition status and severity of critical illness. Well-nourished adult patients without critical illness can have enteral nutrition delayed for seven to fourteen days if oral intake is inadequate, whereas critically ill adults should receive enteral nutrition within twenty-four to forty-eight hours if stable. Parenteral nutrition is indicated within three to five days for nutritionally at-risk adults who cannot meet needs via enteral routes.

Your care plan must respect specific intervention windows:

• Initiate enteral nutrition within 24 to 48 hours for critically ill adults if oral intake is insufficient.
• Start parenteral nutrition within 3 to 5 days for adults at nutrition risk who cannot reach oral or enteral goals.
• Avoid initiating parenteral nutrition in adults with severe metabolic instability until their condition improves.

2. Overview and Indications for Parenteral Nutrition

Parenteral nutrition is the intravenous delivery of nutrients when the gastrointestinal tract cannot be accessed or is nonfunctional, and it is categorized into two main types of admixtures. Up to 40 different chemical components can be contained in a parenteral nutrition mixture. In the United States in 2014, 292,655 hospital stays involved parenteral nutrition.

Parenteral nutrition is the intravenous delivery of nutrients when the gastrointestinal tract cannot be accessed or is nonfunctional, guided by strict clinical criteria and interdisciplinary teams.

Infusion Routes and Osmolarity

Parenteral nutrition osmolarity is driven primarily by dextrose, amino acids, and electrolytes. Dextrose contributes about 5 mOsm/g, amino acids contribute about 10 mOsm/g, and electrolytes contribute about 1 mOsm/mEq. A 1-L parenteral nutrition solution providing 150 g of dextrose, 50 g of amino acids, 20 g of lipid injectable emulsion, and 150 mEq of electrolytes yields an estimated osmolarity of 1414 mOsm/L.

Peripheral veins can generally tolerate a maximum osmolarity of approximately 900 mOsm/L in adults. Hyperosmolar solutions exceeding 1000 mOsm/L must be delivered into a large central vein like the superior vena cava. Patients considered for peripheral parenteral nutrition must have available peripheral venous access, tolerate increased fluid volumes, and require therapy for less than 2 weeks.

Ensure peripheral venous access is available. Verify the patient can tolerate increased fluid volumes of up to 2 to 3 liters per day in a 60-kg adult. Limit the anticipated duration of peripheral parenteral nutrition to less than 2 weeks. Avoid peripheral parenteral nutrition in patients with significant malnutrition, severe metabolic stress, large nutrient needs, fluid restriction, or renal and hepatic compromise.

Clinical Indications and Caution Criteria

Parenteral nutrition is indicated when enteral nutrition fails, is contraindicated, or when the gastrointestinal tract is nonfunctional for a prolonged period, guided by ASPEN guidelines. Specific indicators include paralytic ileus, mesenteric ischemia, small bowel obstruction, select gastrointestinal fistulas, and anticipated prolonged starvation following surgery or critical illness.

Exhaust or trial enteral nutrition using appropriate postpyloric tube placement before initiating central parenteral nutrition. Withhold or withdraw parenteral nutrition during severe clinical conditions like severe hyperglycemia, azotemia, encephalopathy, hyperosmolality, and severe fluid and electrolyte disturbances. Apply parenteral nutrition in patients with moderate to severe malnutrition undergoing surgery for upper gastrointestinal cancer when a prolonged period of gastrointestinal dysfunction is expected.

Monitor glucose and withhold or adjust parenteral nutrition if levels exceed 300 mg/dL. Evaluate blood urea nitrogen and exercise caution if levels exceed 100 mg/dL. Check serum osmolality and restrict parenteral nutrition if values surpass 350 mOsm/kg. Assess serum sodium and maintain caution if sodium is greater than 150 mEq/L. Correct hypokalemia if potassium drops below 3 mEq/L. Monitor chloride levels and address hyperchloremic metabolic acidosis if chloride exceeds 115 mEq/L or alkalosis if chloride drops below 85 mEq/L. Treat hypophosphatemia if phosphorus falls below 2 mg/dL.

Avoid routine parenteral nutrition use in patients receiving chemotherapy or radiation unless they are malnourished and anticipated to be unable to absorb nutrients for 7 to 14 days. Assess patient capabilities, home environment safety, and family support prior to discharging a patient on home parenteral nutrition. Utilize a nutrition consult form as an educational tool for clinicians to document variables identifying potential parenteral nutrition candidates. Oversee nutrition support programs using an interdisciplinary team of experienced clinicians to supervise formulations and monitor patient status.

3. Vascular Access Devices and Management

The distinction between peripheral and central vascular access depends entirely on the position of the distal catheter tip rather than the initial entry point. A peripheral venous catheter terminates in a peripheral vein of the hand, arm, scalp, or foot. A central vascular access device must have its tip reach the central circulation, specifically terminating in the lower one-third of the superior vena cava or cavoatrial junction, or within the inferior vena cava above the diaphragm for femoral insertions. The superior vena cava has an approximate length of 7 cm, a diameter of 20-30 mm, and an estimated blood flow of 2000 mL/min. Peripheral venous catheters are prone to high rates of technical failure, such as infiltration and phlebitis, requiring strict monitoring and prompt removal. You should use peripheral lines only for short-term therapy with dilute nutrient admixtures under 900 mOsm/L, noting that infusion phlebitis risk increases after 96 hours in situ.

Central venous access devices are essential for delivering central parenteral nutrition but require strict insertion bundles, lumen selection, and infection control protocols.

Central venous access devices fall into three broad categories—nontunneled catheters, tunneled catheters, and implanted ports—each suited for specific therapy durations and settings. Nontunneled catheters are common in acute care for short durations. Tunneled catheters like Broviac and Hickman use a subcutaneous tunnel and Dacron cuff to block microbe migration. Implanted ports reduce maintenance needs and preserve body image but risk contamination if accessed continuously with a needle. Multilumen devices increase the risk of central line-associated bloodstream infection and deep vein thrombosis due to frequent manipulation and larger calibers. Restricting one lumen exclusively for parenteral nutrition reduces manipulation frequency and prevents incompatible medication co-infusions. Using 20 single-lumen catheters in lieu of multilumen versions can avoid 1 central line-associated bloodstream infection. Triple-lumen peripherally inserted central catheters carry a 20-fold increase in deep vein thrombosis risk compared to single-lumen versions. Obtaining blood samples through central vascular access devices increases microbial contamination risks and frequently yields spurious laboratory values leading to patient harm. A prospective study reported 63 incidents of spurious blood work in 34 parenteral nutrition recipients, while a 10.9% reduction in blood culture contamination rates followed decreased blood draws from central lines.

Infection Prevention and Catheter Removal

Central line-associated bloodstream infections originate primarily through extraluminal skin flora contamination early on or intraluminal hub contamination during prolonged dwell times. Most central line-associated bloodstream infections occur five days or more after device insertion. Classifying infections into early-onset insertion-related cases and late-onset maintenance-related cases helps organizations prioritize preventive interventions. Nosocomial bloodstream infections carry an attributed mortality of 12%-25%, and 71.7% of central line-associated bloodstream infections occur 5 days or more after insertion. Implementing strict evidence-based insertion and maintenance bundles drastically reduces infection rates by treating preventive steps as an indivisible protocol, reporting a 66% sustained reduction in central line-associated bloodstream infection rates.

You must follow these practices to maintain vascular access safety:

• Review ongoing need for central venous access daily in acute care and transition promptly to oral or enteral intake.
• Practice consistent hand hygiene and avoid routine line disconnections.
• Change parenteral nutrition administration tubing every 24 hours.
• Perform skin antisepsis with chlorhexidine.
• Change transparent sterile dressings every 7 days and gauze dressings every 2 days.
• Scrub needleless adaptors immediately before use with 70% alcohol or chlorhexidine.
• Flush before and after parenteral nutrition or medication administration using saline or heparinized saline.

Prompt removal of central vascular access devices is required when therapy ends or when unresolvable infections occur, while adhering strictly to safety steps to prevent fatal air embolism. Scheduled catheter exchanges do not reduce infection rates, but unresolvable infections like Staphylococcus aureus or candidemia require immediate removal. Air embolism is the most serious potential complication during catheter termination.

You must execute these steps during catheter removal:

• Place the patient in a supine position with the head down or in the Trendelenburg position.
• Instruct the patient to perform the Valsalva maneuver during catheter removal if possible; otherwise, remove the catheter during exhalation.
• Cover the site with an impermeable dressing and maintain pressure for 5 to 10 minutes to promote hemostasis.
• Instruct the patient to maintain a supine position for 30 minutes after central vascular access device removal.

4. Formulation Components and Nutrient Requirements

Parenteral nutrition formulations consist of carefully balanced macronutrients, micronutrients, and electrolytes tailored to patient age and metabolic stress.

Formulations combine amino acids, dextrose, and lipid injectable emulsions along with trace elements and vitamins. You must account for calcium and phosphate solubility limitations and aluminum contamination risks.

Macronutrient Substrates

Dextrose is the most common carbohydrate energy substrate in parenteral nutrition, providing 3.4 kcal/g in its hydrated form. Commercial solutions range from 2.5% to 70% concentrations and have an acidic pH between 3.5 and 6.5. Concentrations greater than 10% require central vein administration because lower peripheral veins are prone to thrombophlebitis.

Crystalline amino acids provide standard or specialized protein intake, calculated assuming a nitrogen content of 16%. Standard stock concentrations range from 3% to 20%, with 8.5%, 10%, and 15% most frequent. Pediatric formulas contain higher amounts of branched-chain amino acids and lower methionine and phenylalanine to match breastfed infant plasma levels.

Lipid injectable emulsions provide essential fatty acids and energy, with specific formulation and infusion recommendations depending on patient age and oil composition. Approved emulsions include 100% soybean oil, a 2-oil mixture of olive and soybean oil, a 4-oil mixture including medium-chain triglycerides and fish oil, and 100% fish oil for pediatrics. Soybean-based emulsions supply 1.1 to 3 kcal/mL depending on concentration, while general fat provides 9 kcal/g.

Nutrient Requirements and Shortage Management

Nutrient intake targets for adult patients differentiate between stable individuals and those experiencing critical illness. Critically ill adults require higher protein goals between 1.5 and 2 g/kg/d with carbohydrate limitations, while stable patients require 0.8 to 1 g/kg/d of protein and 20 to 30 kcal/kg/d total energy.

Pediatric and neonatal parenteral nutrition goals depend heavily on age, weight, and developmental stage, requiring customized dosing for energy, protein, and fluids. Preterm neonates have high protein needs up to 4 g/kg/d and energy requirements reaching 120 kcal/kg, whereas adolescent requirements approach adult values.

Component shortages require systematic conservation strategies, alternative sourcing, and active protocol adjustments to prevent patient harm. You must implement conservation strategies early and assess ongoing nutritional indications.

You must follow these clinical practices during component shortages and administrations:

• Implement conservation strategies early and assess the true clinical indication for parenteral nutrition.
• Switch stable patients to oral or enteral nutrients excluding malabsorption syndromes.
• Reserve parenteral products for those receiving nutrition exclusively or with a therapeutic medical need.
• Purchase only as much as needed without hoarding or stockpiling.
• Report patient problems related to shortages to the Institute for Safe Medication Practices Medication Errors Reporting Program.
• Provide a protein intake of 1 to 1.5 g/kg/d on day one for adult patients.
• Administer an initial maximum carbohydrate dose of 150 to 200 g/d in adults, or 100 to 150 g/d for patients with diabetes mellitus or stress hyperglycemia.
• Initiate amino acids in premature infants at doses of 2 to 2.5 g/kg/d or higher within a few hours after birth.
• Initiate lipid emulsions within 3 days of birth for neonates starting at 1.5 to 2 g/kg/d and advancing daily.

5. Compounding, Stability, and Quality Control

Pharmacist review and verification of parenteral nutrition orders are critical clinical and pharmaceutical safety steps before compounding. You must evaluate macronutrients, micronutrients, and nonnutrient medications against patient indication, body weight, organ function, and labs. A national survey reveals that 23% of organizations dedicate no full-time staff to pharmacist review.

Safe compounding requires automated devices, adherence to USP Chapter 797 standards, strict additive sequences, and rigorous stability checks for multivalent cations.

Automated compounding devices enhance accuracy and efficiency in parenteral nutrition preparation compared to manual compounding. These devices allow custom volumes greater than 10 milliliters to be pumped from stock containers, enforcing proper sequences and reducing human error. You should restrict manual compounding to component volumes that automated devices cannot accurately deliver or cases of component interactions.

Follow these vendor-validated setup steps for automated compounding:

• Perform initial setup and vendor-validated processes with 2 staff members using an independent double-check process.
• Verbally affirm all additives and base solutions during setup.
• Use barcode technology to verify products during setup and ingredient replacement.
• Trace tubing from the source container to the port where it attaches to the automated compounding device.

Order Review and Automated Compounding

United States Pharmacopeia Chapter 797 defines risk levels for compounded sterile products that dictate mandatory beyond-use dating limits. Beyond-use dating cannot exceed Chapter 797 limits without formal sterility testing and can be further shortened by chemical stability and compatibility concerns. The maximum beyond-use dating for pharmacy-prepared parenteral nutrition formulations stored at room temperature is 30 hours, dropping to 9 days under refrigeration.

Quality assurance procedures during compounding ensure accuracy, precision, and safe finished product release. You can assess accuracy volumetrically, gravimetrically, chemically using USP-approved ranges of 95% to 105%, or via refractometry for dextrose concentration.

Stability, Compatibility, and Quality Assurance

Following a specific manual compounding additive sequence is vital to preserve physical stability and avoid dangerous incompatibilities. Dextrose and lipid injectable emulsions should never be added directly to one another because low pH disrupts the emulsion.

Total nutrient admixture stability depends on maintaining a negative surface charge on fat droplets, which can be disrupted by low pH and multivalent cations. Zeta potential prevents fat droplets from coalescing into larger globules above 1 micrometer, which can lodge in pulmonary vasculature. The most favorable pH range for lipid injectable emulsion stability is 6 to 9, while 2% is the minimum concentration below which instability may occur.

Federal regulations cap maximum aluminum load in large-volume parenterals at 25 micrograms per liter. The FDA selects 4 to 5 micrograms per kilogram per day as the upper limit of acceptable aluminum exposure. Unbound aluminum is filtered by kidneys, but 95% of aluminum is bound to protein and cannot be readily excreted, leading to tissue deposition and conditions like encephalopathy and osteomalacia.

6. Administration Safety, Devices, and Complications

Administration is the most vulnerable phase for parenteral nutrition errors, requiring in-line filters, smart pumps, and careful monitoring for refeeding syndrome and organ complications.

Safe Administration Practices and Medical Devices

You face the highest risk of medication errors during the administration phase of parenteral nutrition. Neonates and pediatric patients are especially vulnerable to rapid over-infusion and incorrect infusion rates. Studies indicate that administration errors account for 35 percent of all parenteral nutrition errors.

A review of National Health System reports highlighted multiple incidents where aqueous or fat components were infused at incorrect rates, resulting in severe harm or death in babies.

To protect patients, you must follow strict procedural steps:

• Inspect PN formulations prior to infusion and at regular intervals for precipitants, particulates, or instability.
• Trace all tubing back to its origin before connecting devices or infusions.
• Recheck connections and trace all patient tubes and catheters at the start of each shift and upon unit transfer.
• Use independent double-checks for critical phases like order verification or pump programming when implemented strategically.
• Place in-line filters as close to the patient as possible.
• Change filters and administration sets with each new PN container or every 24 hours for continuous infusions.
• Fill filters immediately before initiating the infusion rather than priming them in advance.
• Completely set up the first infusion and program its pump before setting up a second infusion.

A 0.22-micrometer filter is the recommended size for dextrose/amino acid formulations. A 1.2-micrometer filter is required for total nutrient admixtures and lipid emulsions. You must respect a maximum hang time and container use interval of 12 hours for separately infused lipid emulsions.

Metabolic and Organ-Level Complications

Rapid nutrition support can trigger refeeding syndrome. When nutrition starts, glucose stimulates an insulin response that drives intracellular uptake of ions, resulting in a sudden drop in serum concentrations. Profound hypophosphatemia is the hallmark, accompanied by low potassium, magnesium, and potential fluid overload leading to pulmonary edema.

You must manage metabolic risk by following specific practices:

• Correct existing electrolyte disturbances before PN begins.
• Provide a reduced level of energy in the initial PN formulation.
• Supplement thiamin within the first 3 days of PN.
• Vigilantly monitor serum electrolytes and aggressively correct deficits.

Long-term parenteral nutrition therapy is associated with intestinal failure-associated liver disease, parenteral nutrition-associated cholestasis, and metabolic bone disease. Conjugated bilirubin concentrations above 2 milligrams per deciliter define cholestasis. You must screen for bone mineral density loss, osteopenia, and osteoporosis using dual energy x-ray absorptiometry scans after 6 months of therapy.

7. Clinician Competencies, Home Care, and Advanced Technology

Specialized training models, interdisciplinary home care management, multichamber bags, and electronic health record optimizations ensure longitudinal patient safety and continuity of care.

Prescribing and Administration Competencies

Institutions should implement a standardized 7-day training and privileging model for clinicians who prescribe parenteral nutrition. You must complete certification or didactic coursework followed by direct practice evaluations:

• Complete a didactic or interactive course including indications, venous access, volume, macronutrient and micronutrient requirements, fluid and electrolyte balance, drug-nutrient interactions, ordering, and monitoring with pre- and post-tests.
• Complete at least 10 PN orders for initial competency evaluation via patient case scenarios or actual patients under the supervision of an experienced preceptor.
• Follow these patients and modify daily PN orders over a period of several days to demonstrate the ability to adapt to changing clinical conditions.
• Use the PN Order-Writing Competency Tool during evaluation.
• Re-evaluate competency annually or every other year via continuing education and assessment of at least 5 cases using the competency tool.

Bedside nurses administering parenteral nutrition complete similar structured training programs and supervised evaluations to demonstrate ongoing competency.

Home Parenteral Nutrition and EHR Integration

Home parenteral nutrition enables stable patients to receive long-term nutrition support outside the hospital through structured discharge planning, clinical monitoring, and patient education. Successful home care relies on durable medical equipment providers, comprehensive home care nutrition support clinician teams, emergency planning, and quality-of-life evaluations. Medicare covers home parenteral nutrition under the Prosthetic Device benefit strictly for patients with a permanent, severe pathology of the alimentary tract lasting 3 months or longer.

Before initiating home nutrition support, you must evaluate the home environment to ensure physical safety and operational reliability:

• Explore if the neighborhood is accessible to the home healthcare provider for delivery and professional visits.
• Verify if the environment is clean with reliable utilities including sanitary water, electricity, refrigeration, storage space, electrical outlets, and telephone.
• Assess if the patient can move safely around the house and to the bathroom avoiding stairs or carpeting hazards.
• Determine if the patient or caregiver is willing and able to learn home infusion procedures and equipment operation.
• Confirm if the caregiver is willing and able to provide additional needed assistance for home care.
• Evaluate if the patient or caregiver can learn to recognize problems and contact help from home healthcare or emergency services.
• Ensure laboratory monitoring is available as frequently as needed to prevent fluid and electrolyte complications.

Building and optimizing electronic health records for nutrition care must be treated as a clinical project involving nutrition experts rather than solely an information systems project. EHR systems should use standardized screening tools and clinical decision support alerts to trigger further nutrition workflow steps.

10 Key Ideas

1. The American Society for Parenteral and Enteral Nutrition establishes clinical standards for safe prescription, compounding, vascular access management, and administration of parenteral nutrition therapy across care settings.
2. Adult malnutrition is diagnosed when a patient demonstrates at least two of six specific clinical characteristics—such as weight loss, reduced muscle mass, or insufficient intake—while inflammation invalidates traditional visceral proteins like albumin as nutritional markers.
3. Parenteral nutrition is indicated when enteral nutrition fails, is contraindicated, or when the gastrointestinal tract is nonfunctional for a prolonged period, guided by strict clinical criteria and interdisciplinary teams.
4. Central venous access devices are essential for delivering central parenteral nutrition but require strict insertion bundles, lumen selection, and infection control protocols to prevent catheter-related bloodstream infections.
5. Parenteral nutrition formulations consist of carefully balanced macronutrients, micronutrients, and electrolytes tailored to patient age and metabolic stress while accounting for solubility limitations and aluminum contamination risks.
6. Safe compounding requires automated devices, adherence to United States Pharmacopeia Chapter 797 standards, strict additive sequences, and rigorous stability checks for multivalent cations.
7. Administration requires in-line filters, smart pumps, strict tube tracing, and continuous monitoring because it represents the most vulnerable phase for parenteral nutrition errors.
8. Refeder syndrome is managed by correcting electrolyte disturbances, providing reduced initial energy levels, supplementing thiamin, and vigilantly monitoring serum concentrations.
9. Institutions must implement standardized training and privileging models for clinicians who prescribe parenteral nutrition to ensure ongoing competency and patient safety.
10. Home parenteral nutrition enables stable patients to receive long-term nutrition support outside the hospital through structured discharge planning, environmental evaluations, and clinical monitoring.